H. Lundbeck A/S (0ND5.L)

35.78 +0.20 (+0.56%) At close: 05:54PM BST

H. Lundbeck A/S

Ottiliavej 9
Valby 2500
Denmark
45 36 30 13 11
https://www.lundbeck.com

Sector(s): 
Industry: 
Full-time employees: 5,681

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Charl van Zyl	President & CEO	36.9M	N/A	1967
Mr. Joerg Hornstein	CFO & Executive VP of Corporate Functions	8.5M	N/A	1977
Mr. Lars Bang	Executive Vice President of Product Development & Supply	7.9M	N/A	1962
Dr. Per Johan Luthman	Executive Vice President of Research & Development	8.8M	N/A	1959
Dr. Tarek Samad Ph.D.	Senior VP & Head of Research	N/A	N/A	N/A
Mr. Palle Holm Olesen	Chief Specialist & VP of Investor Relations	N/A	N/A	N/A
Ms. Dianne Holto	Executive Vice President of People & Organization	N/A	N/A	1973
Mr. Ole Chrintz	Senior Vice President of International Markets	N/A	N/A	1958
Dr. Rupert Sandbrink M.D., Ph.D.	Senior VP & Head of Clinical Development	N/A	N/A	1964
Mr. Bjorn R. Mogensen	Senior Vice President of Group Finance	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in DKK.

Description

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.

Corporate governance

H. Lundbeck A/S’s ISS governance QualityScore as of 29 April 2024 is 2. The pillar scores are Audit: 4; Board: 3; Shareholder rights: 9; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.